Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Gøtzsche, Peter C ^a   Johansen, Helle Krogh ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN CONCENTRATE; LEUKOCYTE ELASTASE; PLACEBO;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CARBON MONOXIDE DIFFUSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC VARIABILITY; HOSPITAL ADMISSION; HUMAN; LIVER DISEASE; LUNG DISEASE; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANNICULITIS; PHYSICAL DISABILITY; PHYSICAL INACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; WHEEZING;

EID: 84988432114     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007851.pub3     Document Type: Review

References (35)

1. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:360-8.
2. Chapman KR, Burdon JGW, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM. Alpha-1 antitrypsin (A1AT) preserves lung density In homozygous Alpha-1 antitrypsin deficiency (A1ATD): a randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 2013;187:A6069.
3. NCT00261833 Zemaira in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. clinicaltrials.gov/ct2/show/NCT00261833 (accessed 7 August 2015).
4. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. American Journal of Respiratory and Critical Care Medicine 1999;160(5 Pt 1):1468-72.
5. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. European Respiratory Journal 2009;33(6):1345-53. [DOI: 10.1183/09031936.00159408]
6. NCT00263887 Alpha-1-antitrypsin (AAT) to treat emphysema in AAT-deficient patients (EXACTLE) (trial registration). clinicaltrials.gov/ct2/show/NCT00263887?term=antitrypsin&rank=7 (accessed 5 January 2010).
7. Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respiratory Research 2009;10:75.
8. Efficacy and safety of alpha1-proteinase inhibitor (human), modified process (alpha-1 MP) in subjects with pulmonary emphysema due to alpha1 antitrypsin deficiency (AATD) (SPARTA). clinicaltrials.gov/ct2/show/NCT01983241 (accessed 16 June 2016).
9. Alpha-1 Foundation Homepage. www.alphaone.org/ (accessed 9 May 2008).
10. Chalmers TC, Frank CS, Reitman D. Minimizing the three stages of publication bias. JAMA 1990;263:1392-5.
11. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alfa-1 antitrypsin deficiency: a meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009;6(3):177-84.
12. Chen S, Farahati F, Marciniuk D, Mayers I, Boudreau R, Keating T. Human α1-proteinase inhibitor for patients with α1-antitrypsin deficiency [Technology report no 74]. Ottawa: Canadian Agency for Drugs and Technologies in Health 2007.
13. CLS Behring 2008. www.cslbehring.com/s1/cs/enco/1154398192290/content/1154398189443/content.htm (accessed 9 May 2008).
14. Evald T, Dirksen A, Keittelmann S, Viskum K, Kok-Jensen A. Decline in pulmonary function in patients with alpha-1-antitrypsin deficiency. Lung 1990;168(Suppl):579-85.
15. Genetics Home Reference. Alpha-1 antitrypsin deficiency, 2007. ghr.nlm.nih.gov/condition=alpha1antitrypsindeficiency (accessed 16 November 2008).
16. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. International Journal of Technology Assessment in Health Care 1996;12:238-46.
17. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. BMJ 2006;333(7561):231-4.
18. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. Journal of the American Medical Association 2006;295:1645-6.
19. Heresi GA, Stoller JK. Augmentation therapy in a-1 antitrypsin deficiency. Expert Opinion on Biological Therapy 2008;8:515-26.
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Hutchison DCS. Natural history of alpha1-protease inhibitor deficiency. American Journal of Medicine 1988;84(Suppl 6A):3-12.
23. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Medica Scandinavica 1978;204(5):345-51.
24. Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Canadian Respiratory Journal 2012;19:109-16.
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007;356:2457-71.
26. O'Brien ML, Buist NR, Murphey WH. Neonatal screening for alpha1-antitrypsin deficiency. Journal of Pediatrics 1978;92(6):1006-10.
27. Seersholm N, Dirksen A, Hansen NCG, Harving H og Dansk Lungemedicinsk Selskab. Retningslinjer for erstatningsbehandling til patienter med alfa-1-antitrypsinmangel, 2007 [Guidelines for replacement therapy in patients with alpha-1 antitrypsin deficiency]. www.lungemedicin.dk/guidelines/alfa1erstat.pdf (accessed 09 May 2008).
28. Shah P, Ohlsson A. Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD002775]
29. Sharp HL. Alpha-one-antitrypsin deficiency. Hospital Practice 1971;6:83-96.
30. Silverman EK, Sandhaus RA. Alpha1-antitrypsin deficiency. New England Journal of Medicine 2009;360:2749-57.
31. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respiratory Research 2010;11:136.
32. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200, 000 infants. New England Journal of Medicine 1976;294(24):1316-21.
33. Sveger T. Alpha 1-antitrypsin deficiency in early childhood. Pediatrics 1978;62(1):22-5.
34. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
35. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD007851.pub2]